Abstract
Objectives The optimal treatment for elderly patients (age > 70 years) with glioblastoma remains controversial. We conducted a prospective trial in 32 consecutive elderly patients with glioblastoma who underwent surgery followed by radiotherapy (RT) plus concomitant and adjuvant temozolomide. Patients and Methods 32 patients 70 years of age or older with a newly diagnosed glioblastoma and a Karnofsky performance status (KPS) ≥ 70 were treated with RT (daily fractions of 2 Gy for a total of 60 Gy) plus temozolomide at the dose of 75 mg/m2 per day followed by six cycles of adjuvant temozolomide (150–200 mg/m2 for 5 days during each 28-day cycle). The primary endpoint was overall survival (OS). Secondary endpoints included progression free survival (PFS) and toxicity. Results The median OS was 10.6 months and the median PFS was 7 months. The 6-month and 12-month survival rates were 91% and 37%, respectively. The 6-month and 12-month PFS rates were 56% and 16%, respectively. In multivariate analysis KPS was the only significant independent predictive factor of survival (P = 0.01). Adverse effects were mainly represented by neurotoxicity (40%), which resolved in most cases with the use of steroids, and Grade 3–4 hematologic toxicity in 28% of patients. Chemotherapy was stopped in 2 patients, delayed in 9 patients and reduced in 4 patients. Conclusions Standard RT plus concomitant and adjuvant temozolomide is a feasible treatment for elderly patients with newly diagnosed glioblastoma who present with good prognostic factors.
Similar content being viewed by others
References
Fleury A, Menegoz F, Grosclaude P et al (1997) Descriptive epidemiology of cerebral gliomas in France. Cancer 79:1195–2202
Chakrabarti I, Cockburn M, Cozen W et al (2005) A population-based description of glioblastoma multiforme in Los Angeles County, 1974–1999. Cancer 104:2798–806
Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partition analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710
Meckling S, Dold O, Forsyth PA et al (1996) Malignat supratentorial glioma in the elderly: is radiotherapy useful? Neurology 47:901–905
Shih Ha, Betensky RA, Dorfman MV et al (2005) Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiat Oncol Biol Phys 63:704–711
Batchelor TT, Betensky RA, Esposito JM et al (2004) Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 10:228–233
Minniti G, Brada M, Kleihues P, Ohgaki H (2006) Gliomas. In: Gospodarowicz MK, O’Sullivan B, Sobin LH (eds) Prognostic factors in cancer, 3rd edn, Wiley J &Sons, Hoboken, New Jersey
Whittle IR, Denholm SW, Gregor A et al (1991) Management of patients aged over 60 years with supratentorial glioma: lessons from an audit. Surg Neurol 36:106–111
Bauman GS, Fisher BJ, Halperin EC et al (1994) A prospective study of short course RT in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 29:835–839
Thomas R, James N, Guerrero D et al (1994) Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother Oncol 33:113–116
Ford JM, Stenning SP, Bootle DJ et al (1997) A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin Oncol (R Coll Radiol) 9:20–24
Hoegler DB, Davey P (1997) A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neurooncol 33(3):201–214
McAleese JJ, Stenning SP, Ashley S et al (2003) Hypofractionated radiotherapy for poor prognosis malignant glioma: matched pair survival analysis with MRC controls. Radiother Oncol 67:177–182
Roa W, Brasher PMA, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1593–1598
Keime-Guiber F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535
Glantz M, Chamberlain M, Liu Q et al (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266
Chinot OL, Barrie M, Frauger E et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208–2214
Chamberlain MC, Chalmers L (2007) A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol 82:207–209
Stupp R, Mason W, Van der Bent M et al (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med 352:987–96
MacDonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
Mohan DS, Suh JH, Phan JL et al (1998) Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys 42:981–987
Villà S, Vinolas N, Verger Eh et al (1998) Efficacy of radiotherapy for malignant gliomas in elderly patients. Int J Radiat Oncol Biol Phys 42:977–980
Brandes AA, Vastola F, Basso U (2003) A prospective study in glioblastoma multiforme. Cancer 3:657–662
Gilbert MR, Armstrong TS (1996) Glial neoplasms: classification, treatment, and pathways for the future. Oncol Nurs Forum 23:615–625
Pierga JY, Hoang-Xuan K, Feuvret L et al (1999) Treatment of malignant gliomas in the elderly. J Neurooncol 43:187–193
Piccirilli M, Landi A, Salvati M et al (2006 ) Gliomatosis cerebri treatment in 11 elderly patients. J Exp Clin Cancer Res 25:183–187
Mirimanoff RO, Gorlia T, Mason W et al (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Clin Oncol 24:2563–2569
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003
De Sanctis V, Mazzarella G, Osti MF et al (2006) Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme. Anticancer Drugs 17:969–975
Green H, Paul M, Vidal L et al (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82:1052–1059
Lanzetta G, Campanella C, Rozzi A et al (2003) Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Res 23:5159–5164
Aiken RD (1994) Quality-of-life issues in patients with malignant gliomas. Semin Oncol 21:273–275
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Minniti, G., De Sanctis, V., Muni, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88, 97–103 (2008). https://doi.org/10.1007/s11060-008-9538-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-008-9538-0